Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Sylvia S. Gayle"'
Autor:
Neerjah Skantharajah, Shakuntala Baichoo, Tiffany F. Boughtwood, Esmeralda Casas-Silva, Subhashini Chandrasekharan, Sanjay M. Dave, Khalid A. Fakhro, Aida B. Falcon de Vargas, Sylvia S. Gayle, Vivek K. Gupta, Rachele Hendricks-Sturrup, Ashley E. Hobb, Stephanie Li, Bastien Llamas, Catalina Lopez-Correa, Mavis Machirori, Jorge Melendez-Zajgla, Mareike A. Millner, Angela J.H. Page, Laura D. Paglione, Maili C. Raven-Adams, Lindsay Smith, Ericka M. Thomas, Judit Kumuthini, Manuel Corpas
Publikováno v:
Cell Genomics, Vol 3, Iss 10, Pp 100386- (2023)
Summary: A lack of diversity in genomics for health continues to hinder equitable leadership and access to precision medicine approaches for underrepresented populations. To avoid perpetuating biases within the genomics workforce and genomic data col
Externí odkaz:
https://doaj.org/article/d881f6121ace422fbb7fb3a3fb3bcac7
Autor:
Ruth A. Keri, Eli E. Bar, Matthew K. Summers, Sylvia S. Gayle, Bryan M. Webb, Melyssa S. Shively, Raffaella Spina, Kristen L. Weber-Bonk, Jennifer M. Sahni
Publikováno v:
Journal of Biological Chemistry. 294:875-886
Inhibitors of bromodomain and extra-terminal proteins (BETi) suppress oncogenic gene expression and have been shown to be efficacious in many in vitro and murine models of cancer, including triple-negative breast cancer (TNBC), a highly aggressive di
Autor:
Darcie D. Seachrist, Vinay Varadan, Peter C. Scacheri, Steven T. Sizemore, Salendra Singh, Bryan M. Webb, Matthew K. Summers, Ruth A. Keri, Kristen L. Weber-Bonk, Jennifer M. Sahni, Sylvia S. Gayle, Gurkan Bebek, Nicole A. Restrepo
Publikováno v:
Cancer Research. 77:5395-5408
Triple-negative breast cancers (TNBC) are highly aggressive, lack FDA-approved targeted therapies, and frequently recur, making the discovery of novel therapeutic targets for this disease imperative. Our previous analysis of the molecular mechanisms
Publikováno v:
Oncoscience
Autor:
Bryan M. Webb, Ruth A. Keri, Sylvia S. Gayle, Erika K. Ramos, Jenny C. Chang, Darcie D. Seachrist, Jennifer L. Yori, Melissa D. Landis, Kristen L. Weber Bonk, Leslie Cuellar Vite, Jennifer M. Sahni, James E. Bradner
Publikováno v:
Journal of Biological Chemistry. 295:9266
Publikováno v:
Cancer Research. 79:P5-03
Currently, there are no targeted strategies to combat triple negative breast cancer, resulting in poor patient survival. TNBC initially respond well to cytotoxic chemotherapies such as paclitaxel, yet resistance and metastatic recurrence are common.
Publikováno v:
Current Medicinal Chemistry. 20:2486-2499
The standard targeted therapy for HER2-overexpressing breast cancer is the HER2 monoclonal antibody, trastuzumab. Although effective, many patients eventually develop trastuzumab resistance. The dual EGFR/HER2 small molecule tyrosine kinase inhibitor
Autor:
James E. Bradner, Leslie Cuellar Vite, Ruth A. Keri, Bryan M. Webb, Sylvia S. Gayle, Jennifer M. Sahni, Jennifer L. Yori, Jenny C. Chang, Darcie D. Seachrist, Erika K. Ramos, Kristen L. Weber Bonk, Melissa D. Landis
Publikováno v:
J Biol Chem
Bromodomain and extraterminal (BET) proteins are epigenetic “readers” that recognize acetylated histones and mark areas of the genome for transcription. BRD4, a BET family member protein, has been implicated in a number of types of cancer, and BE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34bb848ab1e155946368837a8ad1d619
https://europepmc.org/articles/PMC5095428/
https://europepmc.org/articles/PMC5095428/
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 12:151-162
Lapatinib, a dual EGFR/HER2 kinase inhibitor, is approved for use in patients with trastuzumab-refractory HER2- overexpressing breast cancer. Increased PI3K signaling has been associated with resistance to trastuzumab, although its role in lapatinib
Autor:
Matthew R. Summers, Jennifer M. Brancato, Gurkan Bebek, Ruth A. Keri, Sylvia S. Gayle, Kristen L. Weber-Bonk
Publikováno v:
Cancer Research. 76:4647-4647
Bromodomain and Extra Terminal (BET) proteins are epigenetic “readers” that recognize acetylated histones and mark areas of the genome for transcription. BRD4, a BET family member protein, has been implicated in a number of types of cancer. It ha